Utah Medical Products (UTMD) Receivables (2010 - 2026)

Utah Medical Products' Receivables history runs 17 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• On a quarterly basis, Receivables fell 7.81% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 7.81% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 12.7% from the prior year.
• Receivables improved to $3.6 million in Q1 2026 per UTMD's latest filing, from $3.5 million in the prior quarter.
• Across five years, Receivables topped out at $6.0 million in Q3 2022 and bottomed at $3.5 million in Q3 2023.
• The 5-year median for Receivables is $3.7 million (2024), against an average of $4.1 million.
• Across the five-year window, Receivables surged 37.6% in 2022 and tumbled 42.21% in 2023, its largest moves.
• Year by year, Receivables stood at $5.6 million in 2022, then tumbled by 37.59% to $3.5 million in 2023, then gained by 17.37% to $4.1 million in 2024, then declined by 13.97% to $3.5 million in 2025, then rose by 3.24% to $3.6 million in 2026.
• Per Business Quant, the three latest UTMD Receivables figures stand at $3.6 million (Q1 2026), $3.5 million (Q4 2025), and $3.7 million (Q3 2025).